Tom has more than nine years of operations experience. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Alexs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Emily holds a BS in Graphic Design from James Madison University. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Mike earned his MBA from the Darden Graduate School of Business Administration. Jaime is an Executive Assistant at RA Ventures (RAVen). He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Brian is a IT Operations Manager at RA Capital Management. His research investigated chromatin structure and transcription factor binding. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Pathways to | Harvard Office of Technology Development Jaimie has a BS in Marketing Management from Coastal Carolina University. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Her primary responsibilities are to provide strategic administrative support and to assist the co founder in various external and internal projects She previously held Senior Executive Assistant roles at Genuity Science and Charles River Laboratories, and served as Director of Operations at Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris. He also serves on the board of the American . Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. Andrew is a Software Developer at RA Capital Management. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Daniel Slesinski is an Associate within the Planetary Health division at RA Capital Management. By continuing, you accept the use of these cookies. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. Medicare 'negotiating' drug prices will hurt Americans, not help - STAT Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. James McArthur is an Advisor for RA Capital Management. In addition to The Great American Drug Deal, he is the author of The Entrepreneurs Guide to a Biotech Startup. Special Projects Operations Manager/Chief of Staff. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). Prior to Longitude Capital, Cristina held an Associate Analyst role in Biotechnology Equity Research at Cowen. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Tess Cameron is a Principal on the Investment Team at RA Capital Management. Bethany is a Senior Finance Associate at RA Capital Management. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Eric is the Chief Compliance Officer at RA Capital Management. Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn Mario is a Venture Partner and Head of Vaccines at RA Capital. Mariagrace previously worked as an Executive Assistant at MPM Capital. Tess works on both public and private investments and serves on several company boards. Neil was a founder or founding team member of six companies incubated within RA Ventures, including Lusaris Therapeutics, Eliem Therapeutics ($ELYM), Aerovate Therapeutics ($AVTE), Imbria Pharmaceuticals, and Athenen Therapeutics (acquired by Eliem). Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. Harvey is a Controller at RA Capital Management. Neil Buckley is an EIR at RA Capital. Brendan has more than 18 years of experience as a tax professional. The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Roivant, he . Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Michael conducts due diligence on biotechnology companies at RA Capital. Peter Kolchinsky Number of IPOs: 18. Cosmass academic research has been published in journals such as Cell, Science, and Nature. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. 239 Kelton St, Allston, MA . Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program. She worked previously in desktop publishing and as a freelance designer. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Joe DeMaio is IT Operations Associate at RA Capital Management. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. from Harvard College and an M.B.A. from Harvard Business School. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Pieter holds a BA from Trinity College and a JD from Yale Law School. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. Daniel Bahcheli is an Associate Director at RA Capital Management. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Peter Kolchinsky Founder and CEO RA Capital Management. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. Matt Beverly is a Senior Software Engineer at RA Capital Management. Emily Minkow is a Venture Partner at RA Ventures. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. Prior to co-founding Therapeutics Alliances, Nadim worked in NYUs Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Kolchinsky's mom knew her son was gifted - Boston Business Journal Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. Emily Greenis a Visual Identity Designer at RA Capital Management. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Peter Kolchinsky's Post - LinkedIn TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. Prior to joining RAVen, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Bio Peter Kolchinsky Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Matthew Feresten is a Business Systems Analyst at RA Capital Management. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Sarah began her legal career with Foley, Hoag, & Eliot LLP. From time to time we may post specific open positions, but more often we will create positions for the right people. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Vanderpump Rules' Peter Madrigal's Age. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the companys CSO. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). He holds a Bachelors degree in Electronics and Communications from Anna University, and a Masters degree in Computer Science from Northeastern University. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. Prior to Evotec, Cony worked at IGEN, where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fundraising. Jenna previously held roles as Senior Medical Writer and Analyst at Costello Medical Consulting. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. and Novus Biologicals. Michael holds a B.S. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Prior to RA, he served in a dual role at Merck Research Laboratories (MRL). Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. A funny, joyous romance on the streets of south London, plus Jude Law is a menacing Captain Hook in the new Neverland coming-of-age adventure Simon Wardell Fri 28 Apr 2023 04.00 EDT Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Her primary responsibilities are to assist with all finance operations related to the Firm. His graduate research investigated innate immune responses after intracerebral hemorrhage. Mario has more than two decades of experience in vaccinology, virology and immunology in large pharma, government, academy, and biotech settings. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. James Schneider is the Deputy General Counsel at RA Capital Management. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Phi previously worked as an Executive Assistant at Relay Therapeutics. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Our website uses cookies to distinguish you from other users of our website. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University.

Display Folder Structure In Html, Mike George Agent Net Worth, Articles P